CAR-T cell therapy
A patient's own T cells are collected, engineered with a chimeric antigen receptor (CAR) using a lentiviral vector, expanded and re-infused to kill cancer — an approved one-time living-drug class spanning CD19 lymphoma/leukemia and BCMA multiple myeloma, now advancing toward off-the-shelf allogeneic products.
therapeutics-platforms
7 min